These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33839737)

  • 21. Convalescent serum-derived exosomes: Attractive niche as COVID-19 diagnostic tool and vehicle for mRNA delivery.
    Krishnan A; Gangadaran P; Chavda VP; Jogalekar MP; Muthusamy R; Valu D; Vadivalagan C; Ramani P; Laishevtcev A; Katari NK; Ahn BC
    Exp Biol Med (Maywood); 2022 Jul; 247(14):1244-1252. PubMed ID: 35549570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection.
    Schuh AJ; Satheshkumar PS; Dietz S; Bull-Otterson L; Charles M; Edens C; Jones JM; Bajema KL; Clarke KEN; McDonald LC; Patel S; Cuffe K; Thornburg NJ; Schiffer J; Chun K; Bastidas M; Fernando M; Petropoulos CJ; Wrin T; Cai S; Adcock D; Sesok-Pizzini D; Letovsky S; Fry AM; Hall AJ; Gundlapalli AV
    Microbiol Spectr; 2022 Aug; 10(4):e0124722. PubMed ID: 35856710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Convalescent plasma for SARS-CoV-2 infection: win or learn.
    Contreras-Barbeta E; Millan A; Rello J
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34531275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.
    Yi Z; Ling Y; Zhang X; Chen J; Hu K; Wang Y; Song W; Ying T; Zhang R; Lu H; Yuan Z
    Emerg Microbes Infect; 2020 Dec; 9(1):1988-1996. PubMed ID: 32844713
    [No Abstract]   [Full Text] [Related]  

  • 26. Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant.
    Villas-Boas LS; Paula AV; Silva ARD; Paiao HGO; Tozetto-Mendoza TR; Manuli ER; Leal FE; Ferraz ABC; Sabino EC; Bierrenbach AL; Witkin SS; Mendes-Correa MC
    Clinics (Sao Paulo); 2022; 77():100068. PubMed ID: 35767900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma.
    Tonn T; Corman VM; Johnsen M; Richter A; Rodionov RN; Drosten C; Bornstein SR
    Lancet Microbe; 2020 Jun; 1(2):e63. PubMed ID: 32835332
    [No Abstract]   [Full Text] [Related]  

  • 29. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
    Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
    J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.
    Rosati M; Agarwal M; Hu X; Devasundaram S; Stellas D; Chowdhury B; Bear J; Burns R; Donohue D; Pessaint L; Andersen H; Lewis MG; Terpos E; Dimopoulos MA; Wlodawer A; Mullins JI; Venzon DJ; Pavlakis GN; Felber BK
    PLoS Pathog; 2021 Sep; 17(9):e1009701. PubMed ID: 34551020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.
    Nguyen D; Xiao J; Simmonds P; Lamikanra A; Odon V; Ratcliff J; Townsend A; Roberts DJ; Harvala H
    J Infect Dis; 2022 Mar; 225(6):971-976. PubMed ID: 34751775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
    Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
    [No Abstract]   [Full Text] [Related]  

  • 33. Convalescent plasma for COVID-19 considerations.
    Adiwinata Pawitan J
    Transfus Apher Sci; 2021 Feb; 60(1):102927. PubMed ID: 32878733
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
    Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
    Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.
    Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F
    Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Convalescent plasma - this is no time for competition.
    Farrugia A; MacPherson J; Busch MP
    Transfusion; 2020 Jul; 60(7):1644-1646. PubMed ID: 32533558
    [No Abstract]   [Full Text] [Related]  

  • 38. Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2.
    Ameratunga R; Woon ST; Steele R; Lehnert K; Leung E; Brooks AES
    Expert Rev Clin Immunol; 2022 Jun; 18(6):557-565. PubMed ID: 35510369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors.
    Kroemer M; Boullerot L; Ramseyer M; Spehner L; Barisien C; Gravelin E; Renaudin A; Cognasse F; Gallian P; Hermine O; Lacombe K; Tiberghien P; Adotévi O
    Front Public Health; 2022; 10():816848. PubMed ID: 35372242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies.
    Estcourt L; Callum J
    N Engl J Med; 2022 May; 386(18):1753-1754. PubMed ID: 35507487
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.